"Ovarian Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Descriptor ID |
D010051
|
| MeSH Number(s) |
C04.588.322.455 C13.351.500.056.630.705 C13.351.937.418.685 C19.344.410 C19.391.630.705
|
| Concept/Terms |
Ovarian Neoplasms- Ovarian Neoplasms
- Neoplasm, Ovarian
- Ovarian Neoplasm
- Ovary Neoplasms
- Neoplasm, Ovary
- Neoplasms, Ovary
- Ovary Neoplasm
- Neoplasms, Ovarian
Ovary Cancer- Ovary Cancer
- Cancer, Ovary
- Cancers, Ovary
- Ovary Cancers
- Ovarian Cancer
- Cancer, Ovarian
- Cancers, Ovarian
- Ovarian Cancers
- Cancer of Ovary
- Cancer of the Ovary
|
Below are MeSH descriptors whose meaning is more general than "Ovarian Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Ovarian Neoplasms".
This graph shows the total number of publications written about "Ovarian Neoplasms" by people in this website by year, and whether "Ovarian Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 3 | 0 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 2 | 4 |
| 2005 | 10 | 1 | 11 |
| 2006 | 10 | 0 | 10 |
| 2007 | 11 | 0 | 11 |
| 2008 | 14 | 1 | 15 |
| 2009 | 12 | 0 | 12 |
| 2010 | 6 | 1 | 7 |
| 2011 | 14 | 4 | 18 |
| 2012 | 11 | 0 | 11 |
| 2013 | 21 | 2 | 23 |
| 2014 | 16 | 0 | 16 |
| 2015 | 18 | 0 | 18 |
| 2016 | 23 | 0 | 23 |
| 2017 | 26 | 2 | 28 |
| 2018 | 25 | 2 | 27 |
| 2019 | 27 | 2 | 29 |
| 2020 | 16 | 0 | 16 |
| 2021 | 19 | 1 | 20 |
| 2022 | 18 | 0 | 18 |
| 2023 | 9 | 0 | 9 |
| 2024 | 13 | 1 | 14 |
| 2025 | 11 | 0 | 11 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.
-
Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer. Cells. 2026 Jan 30; 15(3).
-
Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours. Clin Transl Med. 2026 Jan; 16(1):e70568.
-
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026). J Clin Oncol. 2026 Jan 20; 44(3):153-163.
-
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review. Gynecol Oncol. 2026 Jan; 204:218-227.
-
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. Ann Oncol. 2026 Apr; 37(4):503-520.
-
A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO. Gynecol Oncol. 2025 Aug; 199:96-102.
-
P53-Induced Autophagy Degradation of NKX3-2 Improves Ovarian Cancer Prognosis. Cells. 2025 05 22; 14(11).
-
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor). BMC Cancer. 2025 Mar 18; 25(1):500.
-
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Mar 13; 13(3).
-
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Jan 11; 13(1).